MPA influences tumor cell proliferation, migration, and invasion induced by RANKL through PRB involving the MAPK pathway in endometrial cancer

Oncology Reports

Volumn 33, Issue 2, 2015, Pages 799-809

  Wang, Jing ^a   Sun, Xiao ^a   Zhang, Huijuan ^a   Wang, Yudong ^a   Li, Yuhong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Endometrial cancer; MPA; Progesterone receptor B; Receptor activator of nuclear factor B; Receptor activator of nuclear factor B ligand

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEDROXYPROGESTERONE ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PROGESTERONE RECEPTOR B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROGESTERONE RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; ENDOMETRIAL HYPERPLASIA; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MEDROXYPROGESTERONE ACETATE; MICE; NEOPLASM INVASIVENESS; RANK LIGAND; RECEPTORS, PROGESTERONE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919420829     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3651     Document Type: Article

References (28)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Di Cristofano A and Ellenson LH: Endometrial carcinima. Annu Rev Pathol 2: 57-85, 2007.
3. Salvesen HB, Haldorsen IS and Trovik J: Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 13: e353-e361, 2012.
4. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al: OPGL is a key regulator of osteoclastoGenesis, lymphocyte development and lymph-node organoGenesis. Nature 397: 315-323, 1999.
5. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, et al: The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103: 41-50, 2000.
6. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P and Brisken C: Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 107: 2989-2994, 2010.
7. Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D and Dougall WC: A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 277: 44347-44356, 2002.
8. Darnay BG, Haridas V, Ni J, Moore PA and Aggarwal BB: Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem 273: 20551-20555, 1998.
9. Mori K, Le Goff B, Berreur M, Riet A, Moreau A, Blanchard F, Chevalier C, Guisle-Marsollier I, Léger J, Guicheux J, et al: Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol 211: 555-562, 2007.
10. Zhang L, Teng Y, Zhang Y, Liu J, Xu L, Qu J, Hou K, Yang X, Liu Y and Qu X: C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway. Oncol Lett 3: 395-400, 2012.
11. Gonzalez-Suarez E, Jacob A P, Jones J, Miller R, Roudier-Meyer M P, Erwert R, Pinkas J, Branstetter D and Dougall WC: RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinoGenesis. Nature 468: 103-107, 2010.
12. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, et al: Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98-102, 2010.
13. Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A, Climent F, Soler MT, Muñoz P, Viñals F, et al: RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumoriGenesis and metastasis. Cancer Res 72: 2879-2888, 2012.
14. Schramek D, Sigl V and Penninger JM: RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab 22: 188-194, 2011.
15. Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, et al: Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 6: e19234, 2011.
16. Dai D, Wolf DM, Litman ES, White MJ and Leslie KK: Progesterone inhibits human endometrial cancer cell Growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 62: 881-886, 2002.
17. Leslie KK, Kumar NS, Richer J, Owen G, TaKimoto G, Horwitz KB and Lange C: Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation. Ann NY Acad Sci 828: 17-26, 1997.
18. Ai ZH, Wang J, Wang YD, Lu LH, Tong JQ and Teng YC: Overexpressed epidermal Growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway. Cancer 116: 3603-3613, 2010.
19. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, et al: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696, 2006.
20. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET and Dougall WC: RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis Genes. Prostate 68: 92-104, 2008.
21. Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D and Rédini F: DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone 40: 981-990, 2007.
22. Wittrant Y, Théoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D and Rédini F: RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 1704: 49-57, 2004.
23. Nebreda AR and Porras A: p38 MAP kinases: beyond the stress response. Trends Biochem Sci 25: 257-260, 2000.
24. Schieven GL: The biology of p38 kinase: a central role in infam-mation. Curr Top Med Chem 5: 921-928, 2005.
25. Manning AM and Davis RJ: Targeting JNK for therapeutic beneft: from junk togold? Nat Rev Drug Discov 2: 554-565, 2003.
26. Yamamoto Y and Gaynor RB: Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of infammation and cancer. J Clin Invest 107: 135-142, 2001.
27. Barkett M and Gilmore TD: Control of Apoptosis by Rel/NFkappaB transcription factors. Oncogene 18: 6910-6924, 1999.
28. Hashimoto I, Koizumi K, Tatematsu M, Minami T, Cho S, Takeno N, Nakashima A, Sakurai H, Saito S, Tsukada K and Saiki I: Blocking on the CXCR4/mTOR signaling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal dissemiNated gastric cancer cells. Eur J Cancer 44: 1022-1029, 2008.